ONCOCYTE CORP filed this 8-K on Nov 12, 2024
ONCOCYTE CORP - 8-K - 20241112 - CASH_FLOW

ONCOCYTE CORPORATION

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands)

 

  

Three Months Ended

September 30,

  

Nine Months Ended

September 30,

 
   2024   2023   2024   2023 
CASH FLOWS FROM OPERATING ACTIVITIES:                    
Net loss  $(13,493)  $(6,489)  $(27,152)  $(11,789)
Adjustments to reconcile net loss to net cash used in operating activities:                    
Depreciation and amortization expense   318    404    935    1,289 
Amortization of intangible assets   22    22    66    66 
Stock-based compensation   450    608    1,254    2,276 
Equity compensation for bonus awards and consulting services   14    108    110    108 
Unrealized gain on marketable equity securities       89        (8)
Change in fair value of contingent consideration   7,140    (435)   9,421    (16,947)
Impairment losses       1,811        6,761 
Loss on disposal of discontinued operations               1,521 
Impairment loss on held for sale assets           169    1,283 
Changes in operating assets and liabilities:                    
Accounts receivable   (124)   (166)   275    130 
Inventories   (232)       (232)    
Prepaid expenses and other assets   (295)   78    (345)   645 
Accounts payable and accrued liabilities   649    126    263    (4,193)
Lease assets and liabilities       75    (123)   (43)
Net cash used in operating activities   (5,551)   (3,769)   (15,359)   (18,901)
                     
CASH FLOWS FROM INVESTING ACTIVITIES:                    
Proceeds from sale of equipment       231        354 
Construction in progress and purchases of furniture and equipment   (87)   (17)   (302)   (17)
Cash sold in discontinued operations               (1,372)
Net cash used in investing activities   (87)   214    (302)   (1,035)
                     
CASH FLOWS FROM FINANCING ACTIVITIES:                    
Proceeds from sale of common shares           15,807    13,848 
Financing costs to issue common shares           (538)   (427)
Proceeds from sale of common shares under at-the-market transactions   18        18     
Financing costs for at-the-market sales   (187)       (187)    
Redemption of Series A redeemable convertible preferred shares           (5,389)   (1,118)
Repayment of financing lease obligations   (86)   (30)   (119)   (87)
Net provided by financing activities   (255)   (30)   9,592    12,216 
                     
NET CHANGE IN CASH, CASH EQUIVALENTS (INCLUDES DISCONTINUED OPERATIONS) AND RESTRICTED CASH   (5,893)   (3,585)   (6,069)   (7,720)
                     
CASH, CASH EQUIVALENTS (INCLUDES DISCONTINUED OPERATIONS) AND RESTRICTED CASH, BEGINNING   10,956    19,068    11,132    23,203 
CASH, CASH EQUIVALENTS AND RESTRICTED CASH, ENDING  $5,063   $15,483   $5,063   $15,483